William Blair reissued an outperform rating for TenX, while Cantor Fitzgerald reaffirmed an overweight rating on July 3, 2026.
3 reports, 1 independent
Updated Jul 31
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
William Blair reissued an outperform rating for TenX, while Cantor Fitzgerald reaffirmed an overweight rating on July 3, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TenX
A human centered design and technology studio.
Nothing else this week.
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma on August 20, 2025.
- Cantor Fitzgerald reiterated an Overweight rating on Amazon stock.
- Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
- Berenberg Bank reaffirmed a buy rating and Cantor Fitzgerald reissued a neutral rating on September 8, 2026.
- Cantor Fitzgerald and Citigroup issued rating updates, while MarketBeat reported research notes on Quince Therapeutics.